Efficacy of tenofovir in patients with lamivudine failure is not different from that in nucleoside/nucleotide analogue-naïve patients with chronic hepatitis B

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 4, 2013, Pages 1790-1796

  Baran, Bulent ^a   Soyer, Ozlem Mutluay ^a   Ormeci, Asli Cifcibasi ^a   Gokturk, Suut ^a   Evirgen, Sami ^a   Bozbey, Hamza Ugur ^a   Akyuz, Filiz ^a   Karaca, Cetin ^a   Demir, Kadir ^a   Besisik, Fatih ^a   Onel, Derya ^a   Gulluoglu, Mine ^a   Badur, Selim ^a   Kaymakoglu, Sabahattin ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; CREATININE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PHOSPHATE; TENOFOVIR DISOPROXIL; VIRUS DNA;

ADD ON THERAPY; ADULT; ADVERSE OUTCOME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY DETECTION; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; HYPOPHOSPHATEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS REPLICATION;

ADENINE; ADULT; ANTI-HIV AGENTS; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NUCLEOSIDES; NUCLEOTIDES; ORGANOPHOSPHONATES; RETROSPECTIVE STUDIES;

EID: 84875189825     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02600-12     Document Type: Article

References (24)

1. European Association for the Study of the Liver. 2012. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J. Hepatol 57:167-185.
2. Lok AS, McMahon BJ. 2009. Chronic hepatitis B: update 2009. Hepatology 50:661-662.
3. Heijtink RA, Kruining J, de Wilde GA, Balzarini J, de Clercq E, Schalm SW. 1994. Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob. Agents Chemother. 38:2180-2182.
4. Cherrington JM, Allen SJW, Bischofberger N, Chen MS. 1995. Kinetic interaction of the diphosphates of 9-(2-phosphonylmethoxyethyl)adenine and other anti-HIV active purine congeners with HIV reversetranscriptase and human DNA polymerase-alpha, polymerase-beta and polymerase-gamma. Antivir. Chem. Chemother. 6:217-221.
5. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. 2008. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 359:2442-2455.
6. Marcellin P, Buti M, Gane E, Krastev Z, Flisiak R, Germanidis G, Washington MK, Barnes CN, Flaherty JF, Bornstein JD, McHutchison JG, Heathcote EJ. 2011. Five years of treatment with tenofovir df (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology 54:1011A-1012A.
7. van Bömmel F, Wunsche T, Mauss S, Reinke P, Bergk A, Schurmann D, Wiedenmann B, Berg T. 2004. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 40:1421-1425.
8. van Bömmel F, Zollner B, Sarrazin C, Spengler U, Huppe D, Moller B, Feucht HH, Wiedenmann B, Berg T. 2006. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 44:318-325.
9. van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Huppe D, Stein K, Trojan J, Sarrazin C, Bocher WO, Spengler U, Wasmuth HE, Reinders JG, Moller B, Rhode P, Feucht HH, Wiedenmann B, Berg T. 2010. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 51:73-80.
10. Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, Desmond PV, Roberts SK, Locarnini S, Bowden S, Angus PW. 2011. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 60:247-254.
11. Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. 2004. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir. Ther. 9:353-363.
12. Delaney WEt., Ray AS, Yang H, Qi X, Xiong S, Zhu Y, Miller MD. 2006. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob. Agents Chemother. 50:2471-2477.
13. Yang H, Qi X, Sabogal A, Miller M, Xiong S, WEt Delaney. 2005. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir. Ther. 10:625-633.
14. Brunelle MN, Lucifora J, Neyts J, Villet S, Holy A, Trepo C, Zoulim F. 2007. In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)-ethoxy]- pyrimidine against multidrug-resistant hepatitis B virus mutants. Antimicrob. Agents Chemother. 51:2240-2243.
15. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. 1973. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 60:646-649.
16. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, et al. 1995. Histological grading and staging of chronic hepatitis. J. Hepatol. 22:696-699.
17. Manns M, Jeffers L, Dalekos G, Berg T, Trepo C, Roberts S, Prieto M, Rizzetto M, Sorbel J, Anderson J, Mondou E, Rousseau F. 2008. The antiviral response to tenofovir disoproxil fumarate (TDF) is comparable in lamivudine (LAM)-naïve and LAM-experienced subjects treated for chronic hepatitis B (CHB). J. Hepatol. 48:S33-S33.
18. Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, Kitrinos K, Svarovskaia ES, Miller MD, Sorbel J, Heathcote J, Marcellin P, Borroto-Esoda K. 2011. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 53:763-773.
19. Degertekin B, Hussain M, Tan J, Oberhelman K, Lok AS. 2009. Sensitivity and accuracy of an updated line probe assay (HBV DR v. 3) in detecting mutations associated with hepatitis B antiviral resistance. J. Hepatol. 50:42-48.
20. Berg T, Marcellin P, Zoulim F, Moller B, Trinh H, Chan S, Suarez E, Lavocat F, Snow-Lampart A, Frederick D, Sorbel J, Borroto-Esoda K, Oldach D, Rousseau F. 2010. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 139:1207-1217.
21. Hussain M, Fung S, Libbrecht E, Sablon E, Cursaro C, Andreone P, Lok AS. 2006. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J. Clin. Microbiol. 44: 1094-1097.
22. Hussain M, Chu CJ, Sablon E, Lok AS. 2003. Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. J. Clin. Microbiol. 41:3699-3705.
23. Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouee-Durantel S, Villeneuve JP, Trepo C, Zoulim F. 2005. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 41:1391-1398.
24. Sheldon J, Camino N, Rodes B, Bartholomeusz A, Kuiper M, Tacke F, Nunez M, Mauss S, Lutz T, Klausen G, Locarnini S, Soriano V. 2005. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir. Ther. 10:727-734.